CDR1as promotes arrhythmias in myocardial infarction via targeting the NAMPT-NAD+ pathway

Yunqi Liu,Jiapan Wang,Xiuye Zhao,Wen Li,Yaohua Liu,Xingda Li,Dan Zhao,Jie Yu,Hongyu Ji,Bing Shao,Zhendong Li,Jia Wang,Yilian Yang,Yan Hao,Yuting Wu,Ye Yuan,Zhimin Du

DOI: https://doi.org/10.1016/j.biopha.2023.115267

IF: 7.419

2023-09-01

Biomedicine & Pharmacotherapy

Abstract:Cardiac ventricular arrhythmia triggered by acute myocardial infarction (AMI) is a major cause of sudden cardiac death. We have reported previously that an increased serum level of circular RNA CDR1as is a potential biomarker of AMI. However, the possible role of CDR1as in post-infarct arrhythmia remains unclear. This study in MI mice investigated the effects and underlying mechanism of CDR1as in ventricular arrhythmias associated with MI. We showed that knockdown of CDR1as abbreviated the duration of the abnormally prolonged QRS complex and QTc intervals and decreased susceptibility to ventricular arrhythmias. Optical mapping demonstrated knockdown of CDR1as also reduced post-infarct arrhythmia by increasing the conduction velocity and decreasing dispersion of repolarization. Mechanistically, CDR1as led to the depletion of NAD⁺ and caused mitochondrial dysfunction by directly targeting the NAMPT protein and repressing its expression. Moreover, CDR1as aggravated dysregulation of the Na_V1.5 and Kir6.2 channels in cardiomyocytes, a change which was alleviated by the replenishment of NAD⁺. These findings suggest that anti-CDR1as is a potential therapeutic approach for ischemic arrhythmias.

pharmacology & pharmacy,medicine, research & experimental